首页 > 最新文献

Mediastinum (Hong Kong, China)最新文献

英文 中文
Esophageal duplication cysts: a clinical practice review. 食管重复囊肿:临床实践回顾。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-33
Jessica E Wahi, Fernando M Safdie

Esophageal duplication represents one of the most common types of bronchopulmonary foregut malformations. These rare congenital anomalies occur secondary to embryological aberrations between the 4th and 8th weeks of gestation. In order to be classified as an esophageal cyst a mediastinal cyst must have a close proximity with the esophagus, be lined by alimentary (squamous epithelium) or tracheobronchial mucosa and covered by two smooth muscle layers. These rare anomalies are often asymptomatic during adulthood. However, they can cause symptoms in early childhood, generally during the first 2 years of life. Variations in location, size, presence or absence of heterotopic mucosa, will dictate the clinical presentation. Dysphagia, food impaction, persistent cough and chest pain are common clinical presentations. Imaging studies including esophagram, computed tomography (CT) and magnetic resonance imaging (MRI) can provide key findings to reach the diagnosis. Nonetheless, endoscopic evaluation, particularly endoscopic ultrasound (EUS) is the most valuable tool to determine whether this lesion is cystic versus solid and or if there are abnormal mucosal findings. Needle biopsies are controversial but can help with drainage and to rule out malignant transformation. Therapeutic options include endoluminal drainage. However, more definitive therapies include surgical excision. Open and minimally invasive (laparoscopic and thoracoscopic) techniques have been demonstrated to be safe and effective at completely removing these lesions. Recently, robotic-assisted resections have gained more attention with case reports and series reporting excellent outcomes.

食管重复是支气管肺前肠畸形最常见的类型之一。这些罕见的先天性异常发生继发于胚胎学异常在妊娠4和8周之间。要归类为食道囊肿,纵隔囊肿必须靠近食道,内衬有消化道粘膜(鳞状上皮)或气管支气管粘膜,并被两层平滑肌覆盖。这些罕见的异常在成年期通常无症状。然而,它们可以在儿童早期引起症状,通常在生命的头两年。位置、大小、有无异位粘膜的变化将决定临床表现。吞咽困难,食物嵌塞,持续咳嗽和胸痛是常见的临床表现。影像学检查包括食管造影,计算机断层扫描(CT)和磁共振成像(MRI)可以提供关键的发现,以达到诊断。尽管如此,内镜评估,特别是内镜超声(EUS)是确定该病变是囊性还是实性以及是否有异常粘膜发现的最有价值的工具。针活检是有争议的,但可以帮助引流和排除恶性转化。治疗方案包括肠内引流。然而,更明确的治疗方法包括手术切除。开放和微创(腹腔镜和胸腔镜)技术已被证明在完全切除这些病变方面是安全有效的。最近,机器人辅助切除获得了更多的关注,病例报告和系列报道了良好的结果。
{"title":"Esophageal duplication cysts: a clinical practice review.","authors":"Jessica E Wahi,&nbsp;Fernando M Safdie","doi":"10.21037/med-22-33","DOIUrl":"https://doi.org/10.21037/med-22-33","url":null,"abstract":"<p><p>Esophageal duplication represents one of the most common types of bronchopulmonary foregut malformations. These rare congenital anomalies occur secondary to embryological aberrations between the 4th and 8th weeks of gestation. In order to be classified as an esophageal cyst a mediastinal cyst must have a close proximity with the esophagus, be lined by alimentary (squamous epithelium) or tracheobronchial mucosa and covered by two smooth muscle layers. These rare anomalies are often asymptomatic during adulthood. However, they can cause symptoms in early childhood, generally during the first 2 years of life. Variations in location, size, presence or absence of heterotopic mucosa, will dictate the clinical presentation. Dysphagia, food impaction, persistent cough and chest pain are common clinical presentations. Imaging studies including esophagram, computed tomography (CT) and magnetic resonance imaging (MRI) can provide key findings to reach the diagnosis. Nonetheless, endoscopic evaluation, particularly endoscopic ultrasound (EUS) is the most valuable tool to determine whether this lesion is cystic versus solid and or if there are abnormal mucosal findings. Needle biopsies are controversial but can help with drainage and to rule out malignant transformation. Therapeutic options include endoluminal drainage. However, more definitive therapies include surgical excision. Open and minimally invasive (laparoscopic and thoracoscopic) techniques have been demonstrated to be safe and effective at completely removing these lesions. Recently, robotic-assisted resections have gained more attention with case reports and series reporting excellent outcomes.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/6a/med-07-1.PMC10011867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9131146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The European Reference Network: the keystone for the management of rare thoracic cancers. 欧洲参考网络:罕见胸癌管理的基石。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-10
Rocco Morra, Antonio D'Ambrosio, Erica Pietroluongo, Pietro De Placido, Liliana Montella, Vitoantonio Del Deo, Marianna Tortora, Sabino De Placido, Giovannella Palmieri, Mario Giuliano
© Mediastinum. All rights reserved. Mediastinum 2023;7:7 | https://dx.doi.org/10.21037/med-22-10 Rare tumors are a heterogeneous group of malignancies, which show an incidence rate of <6 per 100,000 people per year, according to the definition of Surveillance of Rare Cancers in Europe (RARECARE) (1). Overall, the estimated incidence of all rare tumors in Europe accounts for 24% of all cancers, with 5-year relative survival for all rare cancers of 48.5% (2). Indeed, rare thoracic tumors include many entities: epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, malignant pleural and pericardial mesothelioma, mediastinal germ cell tumors and mesenchymal tumors (Table 1) (1,3-5). The incidence of these tumors in Europe is the highest in patients aged 65 years and older, with a crude rate of 1.4 per million per year for the epithelial tumor of the trachea, 1.7 per million per year for thymic epithelial tumors, among which malignant thymomas are the most common, and 16 per million per year for the malignant mesothelioma of pleura and pericardium. The 5-years relative survival rate is 14% for the epithelial tumors of the trachea, 65.6% for thymic epithelial tumors, and 5.4% for malignant mesothelioma (5). Detailed data on incidence, prevalence and survival of several types of rare thoracic tumors included in Table 1 were reported in a study of the RARECARE working group, using a large patient database (5). These malignancies present an intrinsic complexity in clinical management, both in the initial diagnostic phase, as well as in the treatment choice, due to scarcity of clinical practice guidelines and also to the lack of randomized clinical trials, which substantially limit treatment options. Moreover, to reduce the diagnostic delay and to improve the appropriateness of treatment choice, clinical centers with adequate patient volumes and expertise should be homogeneously accessible in different geographical areas, also to reduce healthcare migration (3,6,7). Notably, the clinical complexity of rare thoracic tumors systematically requires multidisciplinary team discussion to reach the correct diagnosis and offer the best treatment. In 2008, the European Commission launched the RARECARE project. This is a population-based cancer registry aiming at defining incidence, prevalence and long-term outcome of rare cancers. This project allows to study the epidemiology of these cancers in a large and heterogeneous population (8,9). The results of RARECARE registry led to a second project (RARECAREnet), which updated and enlarged the available information on rare cancers in Europe (10). In addition, the Joint Action on Rare Cancers (JARC) launched in 2016, is another major European initiative, in which 34 partners from different countries belonging to the European Community are involved. This project, coordinated by the National Cancer Institute of Milan (INT), seeks to improve the epidemiological knowledge of r
{"title":"The European Reference Network: the keystone for the management of rare thoracic cancers.","authors":"Rocco Morra,&nbsp;Antonio D'Ambrosio,&nbsp;Erica Pietroluongo,&nbsp;Pietro De Placido,&nbsp;Liliana Montella,&nbsp;Vitoantonio Del Deo,&nbsp;Marianna Tortora,&nbsp;Sabino De Placido,&nbsp;Giovannella Palmieri,&nbsp;Mario Giuliano","doi":"10.21037/med-22-10","DOIUrl":"https://doi.org/10.21037/med-22-10","url":null,"abstract":"© Mediastinum. All rights reserved. Mediastinum 2023;7:7 | https://dx.doi.org/10.21037/med-22-10 Rare tumors are a heterogeneous group of malignancies, which show an incidence rate of <6 per 100,000 people per year, according to the definition of Surveillance of Rare Cancers in Europe (RARECARE) (1). Overall, the estimated incidence of all rare tumors in Europe accounts for 24% of all cancers, with 5-year relative survival for all rare cancers of 48.5% (2). Indeed, rare thoracic tumors include many entities: epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, malignant pleural and pericardial mesothelioma, mediastinal germ cell tumors and mesenchymal tumors (Table 1) (1,3-5). The incidence of these tumors in Europe is the highest in patients aged 65 years and older, with a crude rate of 1.4 per million per year for the epithelial tumor of the trachea, 1.7 per million per year for thymic epithelial tumors, among which malignant thymomas are the most common, and 16 per million per year for the malignant mesothelioma of pleura and pericardium. The 5-years relative survival rate is 14% for the epithelial tumors of the trachea, 65.6% for thymic epithelial tumors, and 5.4% for malignant mesothelioma (5). Detailed data on incidence, prevalence and survival of several types of rare thoracic tumors included in Table 1 were reported in a study of the RARECARE working group, using a large patient database (5). These malignancies present an intrinsic complexity in clinical management, both in the initial diagnostic phase, as well as in the treatment choice, due to scarcity of clinical practice guidelines and also to the lack of randomized clinical trials, which substantially limit treatment options. Moreover, to reduce the diagnostic delay and to improve the appropriateness of treatment choice, clinical centers with adequate patient volumes and expertise should be homogeneously accessible in different geographical areas, also to reduce healthcare migration (3,6,7). Notably, the clinical complexity of rare thoracic tumors systematically requires multidisciplinary team discussion to reach the correct diagnosis and offer the best treatment. In 2008, the European Commission launched the RARECARE project. This is a population-based cancer registry aiming at defining incidence, prevalence and long-term outcome of rare cancers. This project allows to study the epidemiology of these cancers in a large and heterogeneous population (8,9). The results of RARECARE registry led to a second project (RARECAREnet), which updated and enlarged the available information on rare cancers in Europe (10). In addition, the Joint Action on Rare Cancers (JARC) launched in 2016, is another major European initiative, in which 34 partners from different countries belonging to the European Community are involved. This project, coordinated by the National Cancer Institute of Milan (INT), seeks to improve the epidemiological knowledge of r","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/be/med-07-7.PMC10011864.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9138172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative complications of mediastinal cyst resection and their management. 纵隔囊肿切除术后并发症及处理。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-30
Hana Ajouz, Nestor Villamizar
© Mediastinum. All rights reserved. Mediastinum 2023;7:20 | https://dx.doi.org/10.21037/med-22-30 The incidence of complications after resection of mediastinal cysts is not well described in the literature. The incidence of complications after resection of mediastinal cysts reported in few case reports and small case series vary between 2–7% (1-4). Most complications that occur after resection of mediastinal cysts are similar to those that occur after any thoracic procedure (2,3) (Table 1,2). Sound knowledge of the possible postoperative complications allow the surgical team to anticipate postoperative complications and thus reduce this morbidity.
{"title":"Postoperative complications of mediastinal cyst resection and their management.","authors":"Hana Ajouz,&nbsp;Nestor Villamizar","doi":"10.21037/med-22-30","DOIUrl":"https://doi.org/10.21037/med-22-30","url":null,"abstract":"© Mediastinum. All rights reserved. Mediastinum 2023;7:20 | https://dx.doi.org/10.21037/med-22-30 The incidence of complications after resection of mediastinal cysts is not well described in the literature. The incidence of complications after resection of mediastinal cysts reported in few case reports and small case series vary between 2–7% (1-4). Most complications that occur after resection of mediastinal cysts are similar to those that occur after any thoracic procedure (2,3) (Table 1,2). Sound knowledge of the possible postoperative complications allow the surgical team to anticipate postoperative complications and thus reduce this morbidity.","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/aa/med-07-20.PMC10226888.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intralesional microbleeding in resected thymic cysts indeterminate on imaging. 切除胸腺囊肿的病灶内微出血在影像学上不确定。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-42
Julian A Villalba, Adina Haramati, Michelle Garlin, Fabiola Reyes, Cameron D Wright, Abner Louissaint, Jeanne B Ackman

Background: The propensity of thymic cysts to mimic solid thymic epithelial tumors (TETs) on computed tomography (CT), on account of attenuation values greater than water and thickened or calcified walls, can lead to non-therapeutic thymectomy. These lesions can fluctuate in volume, CT attenuation, and magnetic resonance imaging (MRI) signal over time. We hypothesized that spontaneous hemorrhage and resorption may contribute to their variable appearance over time.

Methods: Completely excised thymic cysts were identified retrospectively over a 20-year period by their pathologic diagnosis. Cysts were excluded if they did not have available presurgical imaging, were not prevascular, were located within or contained an enhancing mass by imaging, or were of non-thymic origin upon microscopic review. Histopathological analysis of all available resected thymic cyst material and radiologic analysis of the cysts on pre-operative imaging were performed.

Results: Upon application of exclusion criteria, we identified 18 thymic cysts from the initial 85 mediastinal cystic specimens. Most cysts were unilocular (11/15, 73%), showed turbid-to-semisolid, hemorrhagic fluid (10/12, 83%) and showed histopathological findings suggestive of intralesional microbleeding (14/18, 78%), remodeling (8/18, 44%), pathological wound healing/scarring of the capsule (16/18, 89%), and fat necrosis in the surrounding thymic tissue (12/18, 67%). On CT, 6/17 (35%) cysts demonstrated wall calcification. Sixty-five percent (11/17) had attenuation values ≥20 Hounsfield units (HU). Two of the 4 cysts imaged by MRI were T1-isointense, one was mixed hyper- and isointense, and one T1-hypointense to muscle, with iso- and hyperintensity indicating hemorrhagic or proteinaceous content. Twenty-five percent (1/4) of cyst walls imaged by MRI were T1/T2-hypointense, indicating presence of calcification, hemosiderin, and/or fibrosis.

Conclusions: Resected thymic cysts in this cohort often showed features suggestive of intralesional microbleeding, inflammation, and fibrosis, which may explain their appearance and behavior over time on CT and MRI.

背景:由于胸腺囊肿的衰减值大于水,壁增厚或钙化,在计算机断层扫描(CT)上,胸腺囊肿倾向于模拟胸腺实体上皮瘤(TETs),可导致非治疗性胸腺切除术。这些病变在体积、CT衰减和磁共振成像(MRI)信号上随时间波动。我们假设自发性出血和吸收可能是导致其随时间变化的原因。方法:通过20年的病理诊断,对完全切除的胸腺囊肿进行回顾性分析。如果囊肿没有术前显像,没有血管前显像,位于或包含增强肿块,或显微镜检查非胸腺起源,则排除囊肿。对所有切除的胸腺囊肿材料进行组织病理学分析,并对囊肿术前影像学进行放射学分析。结果:根据排除标准,我们从最初的85例纵隔囊肿标本中鉴定出18例胸腺囊肿。大多数囊肿为单眼(11/15,73%),呈浑浊至半固体状,出血性液体(10/12,83%),组织病理学表现提示病灶内微出血(14/18,78%),重塑(8/18,44%),病理性伤口愈合/包膜瘢痕(16/18,89%),胸腺周围组织脂肪坏死(12/18,67%)。CT上,6/17(35%)囊肿显示壁钙化。65%(11/17)的衰减值≥20 Hounsfield单位(HU)。MRI成像的4个囊肿中有2个为t1等强度,1个为混合高、等强度,1个为t1低强度到肌肉,等强度和高强度提示出血或蛋白质含量。25%(1/4)的囊肿壁MRI成像为T1/ t2低信号,表明存在钙化、含铁血黄素和/或纤维化。结论:本队列中切除的胸腺囊肿通常表现为病灶内微出血、炎症和纤维化的特征,这可以解释其在CT和MRI上随时间变化的外观和行为。
{"title":"Intralesional microbleeding in resected thymic cysts indeterminate on imaging.","authors":"Julian A Villalba,&nbsp;Adina Haramati,&nbsp;Michelle Garlin,&nbsp;Fabiola Reyes,&nbsp;Cameron D Wright,&nbsp;Abner Louissaint,&nbsp;Jeanne B Ackman","doi":"10.21037/med-22-42","DOIUrl":"https://doi.org/10.21037/med-22-42","url":null,"abstract":"<p><strong>Background: </strong>The propensity of thymic cysts to mimic solid thymic epithelial tumors (TETs) on computed tomography (CT), on account of attenuation values greater than water and thickened or calcified walls, can lead to non-therapeutic thymectomy. These lesions can fluctuate in volume, CT attenuation, and magnetic resonance imaging (MRI) signal over time. We hypothesized that spontaneous hemorrhage and resorption may contribute to their variable appearance over time.</p><p><strong>Methods: </strong>Completely excised thymic cysts were identified retrospectively over a 20-year period by their pathologic diagnosis. Cysts were excluded if they did not have available presurgical imaging, were not prevascular, were located within or contained an enhancing mass by imaging, or were of non-thymic origin upon microscopic review. Histopathological analysis of all available resected thymic cyst material and radiologic analysis of the cysts on pre-operative imaging were performed.</p><p><strong>Results: </strong>Upon application of exclusion criteria, we identified 18 thymic cysts from the initial 85 mediastinal cystic specimens. Most cysts were unilocular (11/15, 73%), showed turbid-to-semisolid, hemorrhagic fluid (10/12, 83%) and showed histopathological findings suggestive of intralesional microbleeding (14/18, 78%), remodeling (8/18, 44%), pathological wound healing/scarring of the capsule (16/18, 89%), and fat necrosis in the surrounding thymic tissue (12/18, 67%). On CT, 6/17 (35%) cysts demonstrated wall calcification. Sixty-five percent (11/17) had attenuation values ≥20 Hounsfield units (HU). Two of the 4 cysts imaged by MRI were T1-isointense, one was mixed hyper- and isointense, and one T1-hypointense to muscle, with iso- and hyperintensity indicating hemorrhagic or proteinaceous content. Twenty-five percent (1/4) of cyst walls imaged by MRI were T1/T2-hypointense, indicating presence of calcification, hemosiderin, and/or fibrosis.</p><p><strong>Conclusions: </strong>Resected thymic cysts in this cohort often showed features suggestive of intralesional microbleeding, inflammation, and fibrosis, which may explain their appearance and behavior over time on CT and MRI.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/fd/med-07-13.PMC10226889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Giant middle mediastinal lesions: when tumor size correlates with mesenchymal origin-a retrospective single-center analysis. 巨大的中纵隔病变:当肿瘤大小与间充质起源相关时——一项回顾性单中心分析。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-49
Stéphane Collaud, Theresa Stork, Hafsa Kaman, Sebastian Bauer, Christoph Pöttgen, Hans-Ulrich Schildhaus, Bastian Schmack, Clemens Aigner

Background: The International Thymic Malignancy Interest Group (ITMIG) proposed an internationally accepted division of the mediastinum into three compartments based on computed tomography (CT): anterior (prevascular), middle (visceral) and posterior (paravertebral) compartment. There is no generally accepted definition for the term "giant" when applied to middle mediastinal lesions. We defined the term "giant" and described our surgical experience in treating patients with giant lesions of the middle mediastinum.

Methods: CT imaging of patients operated in our center from January 2016 to August 2021 for mediastinal lesions was reviewed. Lesions were categorized to one of the ITMIG-defined compartments. Lesion size at diagnosis was measured at its largest diameter on axial CT imaging. Giant middle mediastinal lesions were defined as lesions having a size ≥90th percentile of our middle mediastinal lesion cohort. Patients with giant middle mediastinal lesions were further analyzed.

Results: Thirty-six patients (23%) had lesions located in the middle mediastinal compartment. Most common diagnoses were mediastinal cysts (n=10, 28%), metastatic lesions (n=6, 17%), lymphomas (n=5, 14%), and sarcomas (n=3, 8%). Ninetieth percentile lesion size was 73 mm. As per definition, four patients had giant middle mediastinal lesions. All these four lesions were of mesenchymal origin including oesophageal leiomyoma, synovial sarcoma, leiomyosarcoma and undifferentiated round cell sarcoma. Resection was performed through posterolateral thoracotomy or sternotomy, with or without cardiopulmonary bypass.

Conclusions: The term "giant" could be defined as a mass larger or equal to 73 mm. This definition selected specifically lesions with mesenchymal origin and may therefore guide diagnostic algorithm and patient management.

背景:国际胸腺恶性肿瘤研究小组(ITMIG)提出了一种国际公认的基于计算机断层扫描(CT)将纵隔划分为三个室:前(血管前)、中(内脏)和后(椎旁)室。对于中纵隔病变,“巨大”一词尚无普遍接受的定义。我们定义了“巨大”一词,并描述了我们治疗中纵隔巨大病变患者的手术经验。方法:回顾2016年1月至2021年8月在我中心手术的纵隔病变患者的CT影像。病变被分类到itmig定义的一个区室。诊断时的病变大小在轴向CT成像上以其最大直径测量。巨大中纵隔病变定义为中纵隔病变队列中≥90百分位数的病变。对巨大中纵隔病变患者进行进一步分析。结果:36例(23%)患者病变位于中纵隔室。最常见的诊断是纵隔囊肿(n=10, 28%)、转移性病变(n=6, 17%)、淋巴瘤(n=5, 14%)和肉瘤(n= 3.8%)。第90百分位病变大小为73 mm。根据定义,4例患者有巨大的中纵隔病变。这4例病变均为间质起源,包括食管平滑肌瘤、滑膜肉瘤、平滑肌肉瘤和未分化圆细胞肉瘤。切除通过后外侧开胸或胸骨切开术,有或没有体外循环。结论:“巨”可定义为大于或等于73 mm的肿块。这个定义特别选择了间质起源的病变,因此可以指导诊断算法和患者管理。
{"title":"Giant middle mediastinal lesions: when tumor size correlates with mesenchymal origin-a retrospective single-center analysis.","authors":"Stéphane Collaud,&nbsp;Theresa Stork,&nbsp;Hafsa Kaman,&nbsp;Sebastian Bauer,&nbsp;Christoph Pöttgen,&nbsp;Hans-Ulrich Schildhaus,&nbsp;Bastian Schmack,&nbsp;Clemens Aigner","doi":"10.21037/med-22-49","DOIUrl":"https://doi.org/10.21037/med-22-49","url":null,"abstract":"<p><strong>Background: </strong>The International Thymic Malignancy Interest Group (ITMIG) proposed an internationally accepted division of the mediastinum into three compartments based on computed tomography (CT): anterior (prevascular), middle (visceral) and posterior (paravertebral) compartment. There is no generally accepted definition for the term \"giant\" when applied to middle mediastinal lesions. We defined the term \"giant\" and described our surgical experience in treating patients with giant lesions of the middle mediastinum.</p><p><strong>Methods: </strong>CT imaging of patients operated in our center from January 2016 to August 2021 for mediastinal lesions was reviewed. Lesions were categorized to one of the ITMIG-defined compartments. Lesion size at diagnosis was measured at its largest diameter on axial CT imaging. Giant middle mediastinal lesions were defined as lesions having a size ≥90<sup>th</sup> percentile of our middle mediastinal lesion cohort. Patients with giant middle mediastinal lesions were further analyzed.</p><p><strong>Results: </strong>Thirty-six patients (23%) had lesions located in the middle mediastinal compartment. Most common diagnoses were mediastinal cysts (n=10, 28%), metastatic lesions (n=6, 17%), lymphomas (n=5, 14%), and sarcomas (n=3, 8%). Ninetieth percentile lesion size was 73 mm. As per definition, four patients had giant middle mediastinal lesions. All these four lesions were of mesenchymal origin including oesophageal leiomyoma, synovial sarcoma, leiomyosarcoma and undifferentiated round cell sarcoma. Resection was performed through posterolateral thoracotomy or sternotomy, with or without cardiopulmonary bypass.</p><p><strong>Conclusions: </strong>The term \"giant\" could be defined as a mass larger or equal to 73 mm. This definition selected specifically lesions with mesenchymal origin and may therefore guide diagnostic algorithm and patient management.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/90/med-07-24.PMC10493615.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging evaluation of thymic tumors. 胸腺肿瘤的影像学评价。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-58
Chad D Strange, Mylene T Truong, Jitesh Ahuja, Taylor A Strange, Smita Patel, Edith M Marom

An integral part of managing patients with thymoma and thymic carcinoma is imaging. At diagnosis and staging, imaging helps demonstrate the extent of local invasion and distant metastases which allows the proper stratification of patients for therapy. For decades, the predominant staging system for thymic tumors was the Masaoka-Koga staging system. More recently, however, the International Association for the Study of Lung Cancer, the International Thymic Malignancies Interest Group (ITMIG), the European Society of Thoracic Surgeons, the Chinese Alliance for Research on Thymomas, and the Japanese Association of Research on Thymus partnered together to develop a tumor-node-metastasis (TNM) staging system specifically for thymic tumors based on a retrospective database of nearly 10,000 patients. The TNM 8th edition defines specific criteria for thymic tumors. Imaging also serves to assess treatment response and detect recurrent disease after various treatment modalities. The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is currently used to assess response to treatment. ITMIG recommends certain modifications to RECIST version 1.1, however, in thymic tumors due to unique patterns of spread. While there is often overlap, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) characteristics can help differentiate thymoma and thymic carcinoma, with newer CT and MRI techniques under evaluation showing encouraging potential.

胸腺瘤和胸腺癌患者治疗的一个组成部分是影像学检查。在诊断和分期时,影像学有助于显示局部侵袭和远处转移的程度,从而允许患者进行适当的分层治疗。几十年来,胸腺肿瘤的主要分期系统是Masaoka-Koga分期系统。然而,最近,国际肺癌研究协会、国际胸腺恶性肿瘤研究小组(ITMIG)、欧洲胸外科学会、中国胸腺瘤研究联盟和日本胸腺研究协会共同合作,基于近1万名患者的回顾性数据库,开发了专门针对胸腺肿瘤的肿瘤-淋巴结-转移(TNM)分期系统。TNM第8版定义了胸腺肿瘤的具体标准。成像也用于评估治疗反应和检测各种治疗方式后的复发性疾病。实体肿瘤反应评价标准(RECIST) 1.1版目前用于评估对治疗的反应。然而,由于胸腺肿瘤独特的扩散模式,ITMIG建议对RECIST 1.1版进行某些修改。虽然经常有重叠,但计算机断层扫描(CT)、磁共振成像(MRI)和正电子发射断层扫描/计算机断层扫描(PET/CT)的特征可以帮助区分胸腺瘤和胸腺癌,新的CT和MRI技术正在评估中,显示出令人鼓舞的潜力。
{"title":"Imaging evaluation of thymic tumors.","authors":"Chad D Strange,&nbsp;Mylene T Truong,&nbsp;Jitesh Ahuja,&nbsp;Taylor A Strange,&nbsp;Smita Patel,&nbsp;Edith M Marom","doi":"10.21037/med-22-58","DOIUrl":"https://doi.org/10.21037/med-22-58","url":null,"abstract":"<p><p>An integral part of managing patients with thymoma and thymic carcinoma is imaging. At diagnosis and staging, imaging helps demonstrate the extent of local invasion and distant metastases which allows the proper stratification of patients for therapy. For decades, the predominant staging system for thymic tumors was the Masaoka-Koga staging system. More recently, however, the International Association for the Study of Lung Cancer, the International Thymic Malignancies Interest Group (ITMIG), the European Society of Thoracic Surgeons, the Chinese Alliance for Research on Thymomas, and the Japanese Association of Research on Thymus partnered together to develop a tumor-node-metastasis (TNM) staging system specifically for thymic tumors based on a retrospective database of nearly 10,000 patients. The TNM 8<sup>th</sup> edition defines specific criteria for thymic tumors. Imaging also serves to assess treatment response and detect recurrent disease after various treatment modalities. The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is currently used to assess response to treatment. ITMIG recommends certain modifications to RECIST version 1.1, however, in thymic tumors due to unique patterns of spread. While there is often overlap, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) characteristics can help differentiate thymoma and thymic carcinoma, with newer CT and MRI techniques under evaluation showing encouraging potential.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/ac/med-07-28.PMC10493619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging modalities (MRI, CT, PET/CT), indications, differential diagnosis and imaging characteristics of cystic mediastinal masses: a review. 囊性纵隔肿块的影像学表现(MRI、CT、PET/CT)、适应症、鉴别诊断及影像学特征综述。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-31
Amar Shah, Carlos A Rojas

Cystic mediastinal masses have traditionally represented a diagnostic dilemma with differentiation of malignant masses a particular area of concern. Each imaging modality has strengths and weaknesses in mediastinal imaging-computed tomography (CT) offers increased spatial resolution at the cost of poorer soft tissue differentiation and requiring ionizing radiation, while magnetic resonance imaging (MRI) offers superior soft tissue contrast/characterization at significantly greater cost. Ultrasound offers real-time visualization but is operator and tissue dependent. [18F]fluoro-D-glucose (F-18 FDG) positron emission tomography (F-18 FDG PET) CT provides functional information, but poorer spatial resolution. Recent advances have focused upon the use of magnetic resonance imaging to aid in characterization of cystic mediastinal lesions, particularly in the context of indeterminate CT findings. The mediastinum may be divided into three anatomic compartments: prevascular, visceral, and paravertebral. All three compartments extend superiorly from the thoracic inlet and inferiorly to the diaphragm. These compartments provide a useful framework for categorizing normal and pathologic mediastinal processes. In this article, we will review the imaging characteristics of mediastinal cystic lesions via a case-based review divided by anatomical mediastinal compartments. Characteristic imaging features and troubleshooting are particular areas of focus. Normal variants that may mimic cystic pathology are discussed. The roles of CT and MRI will be emphasized. Cases from our institution are presented as illustrative examples.

囊性纵隔肿块传统上代表了一个诊断困境,恶性肿块的鉴别是一个特别关注的区域。每一种成像方式在纵隔成像中都有优缺点——计算机断层扫描(CT)以较差的软组织分化和需要电离辐射为代价提供了更高的空间分辨率,而磁共振成像(MRI)以更高的成本提供了更好的软组织对比/表征。超声提供实时可视化,但依赖于操作者和组织。[18F]氟- d -葡萄糖(F-18 FDG)正电子发射断层扫描(F-18 FDG PET) CT提供功能信息,但空间分辨率较差。最近的进展集中在使用磁共振成像来帮助表征囊性纵隔病变,特别是在CT表现不确定的情况下。纵隔可分为三个解剖腔室:血管前腔室、内脏腔室和椎旁腔室。这三个隔室都从胸腔入口向上延伸并向下延伸至隔膜。这些隔室为分类正常和病理性纵膈突提供了有用的框架。在这篇文章中,我们将回顾纵隔囊性病变的影像学特征,通过以病例为基础的回顾,以解剖纵隔区室划分。特征成像特性和故障排除是特别关注的领域。正常变异可能模仿囊性病理讨论。强调CT和MRI的作用。本文以我院的案例为例进行了说明。
{"title":"Imaging modalities (MRI, CT, PET/CT), indications, differential diagnosis and imaging characteristics of cystic mediastinal masses: a review.","authors":"Amar Shah,&nbsp;Carlos A Rojas","doi":"10.21037/med-22-31","DOIUrl":"https://doi.org/10.21037/med-22-31","url":null,"abstract":"<p><p>Cystic mediastinal masses have traditionally represented a diagnostic dilemma with differentiation of malignant masses a particular area of concern. Each imaging modality has strengths and weaknesses in mediastinal imaging-computed tomography (CT) offers increased spatial resolution at the cost of poorer soft tissue differentiation and requiring ionizing radiation, while magnetic resonance imaging (MRI) offers superior soft tissue contrast/characterization at significantly greater cost. Ultrasound offers real-time visualization but is operator and tissue dependent. [18F]fluoro-D-glucose (F-18 FDG) positron emission tomography (F-18 FDG PET) CT provides functional information, but poorer spatial resolution. Recent advances have focused upon the use of magnetic resonance imaging to aid in characterization of cystic mediastinal lesions, particularly in the context of indeterminate CT findings. The mediastinum may be divided into three anatomic compartments: prevascular, visceral, and paravertebral. All three compartments extend superiorly from the thoracic inlet and inferiorly to the diaphragm. These compartments provide a useful framework for categorizing normal and pathologic mediastinal processes. In this article, we will review the imaging characteristics of mediastinal cystic lesions via a case-based review divided by anatomical mediastinal compartments. Characteristic imaging features and troubleshooting are particular areas of focus. Normal variants that may mimic cystic pathology are discussed. The roles of CT and MRI will be emphasized. Cases from our institution are presented as illustrative examples.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/7e/med-07-3.PMC10011868.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9138167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
AB004. Radiotherapy for thymic epithelial tumors: what is the optimal dose?—a systematic review 胸腺上皮肿瘤的放射治疗:最佳剂量是多少--系统综述
Pub Date : 2022-12-30 DOI: 10.21037/med-22-ab004
A. Angrisani, R. Houben, F. Marcuse, M. Hochstenbag, J. Maessen, D. de Ruysscher, S. Peeters
Background Thymic epithelial tumors (TETs) are rare thoracic tumors, often requiring multimodal approaches. Surgery represents the first step of the treatment, possibly followed by adjuvant radiotherapy (RT) and, less frequently, chemotherapy. For unresectable tumors, a combination of chemotherapy and RT is often used. Currently, the optimal dose for patients undergoing radiation is not clearly defined. The available guidelines’ recommendations on RT are based on studies with a low level of evidence, where two-dimensional (2D)-RT was widely used. Methods A systematic review of the recent literature regarding the optimal radiation dose for patients with TETs undergoing RT was carried out. It included reports using modern RT techniques such as 3D-CRT, intensity-modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT), or proton therapy. A comprehensive literature search of four databases was conducted following the PRISMA guidelines. Two investigators independently screened and reviewed the retrieved references. Reports with <20 patients, 2D-RT use only, median follow-up time 3 years, three additional studies could be evaluated. A total of 193 patients were analyzed, stratified for prognostic factors (histology, stage, and completeness of resection), and synthesized according to the SWIM method. The paucity and heterogeneity of eligible studies led to controversial results. Overall, a dose escalation for post-operative RT beyond 50 Gy is not recommended for totally resected tumors, platinum-based chemo plus concurrent RT >54 Gy is recommended for unresectable TETs, while a dose below 52 Gy has been defined as "palliative" for recurrent TETs. Conclusions The optimal RT dose for postoperative or primary RT in the era of modern RT did not univocally emerge. Current recommendations remain valid. Doses of 54 Gy or higher can be recommended for definitive RT only. Conversely, this overview can spark new evidence to define the optimal RT dose for each TETs category.
背景胸腺上皮肿瘤(TETs)是一种罕见的胸部肿瘤,通常需要多模式治疗。手术是治疗的第一步,可能是辅助放疗(RT),以及不太常见的化疗。对于不可切除的肿瘤,通常使用化疗和RT的组合。目前,接受放射治疗的患者的最佳剂量还没有明确定义。现有指南对RT的建议基于证据水平较低的研究,其中二维(2D)-RT被广泛使用。方法系统回顾近年来关于TETs患者接受RT的最佳放射剂量的文献。其中包括使用现代RT技术的报告,如3D-CRT、强度调制放射治疗(IMRT)/体积调制电弧治疗(VMAT)或质子治疗。根据PRISMA指南对四个数据库进行了全面的文献检索。两名研究人员对检索到的参考文献进行了独立筛选和审查。对于不可切除的TET,建议使用54 Gy的报告,而对于复发性TET,低于52 Gy的剂量被定义为“姑息性”。结论在现代RT时代,术后或原发性RT的最佳RT剂量并不是唯一出现的。目前的建议仍然有效。54 Gy或更高的剂量仅可用于明确的RT。相反,这一概述可以引发新的证据来定义每个TET类别的最佳RT剂量。
{"title":"AB004. Radiotherapy for thymic epithelial tumors: what is the optimal dose?—a systematic review","authors":"A. Angrisani, R. Houben, F. Marcuse, M. Hochstenbag, J. Maessen, D. de Ruysscher, S. Peeters","doi":"10.21037/med-22-ab004","DOIUrl":"https://doi.org/10.21037/med-22-ab004","url":null,"abstract":"Background Thymic epithelial tumors (TETs) are rare thoracic tumors, often requiring multimodal approaches. Surgery represents the first step of the treatment, possibly followed by adjuvant radiotherapy (RT) and, less frequently, chemotherapy. For unresectable tumors, a combination of chemotherapy and RT is often used. Currently, the optimal dose for patients undergoing radiation is not clearly defined. The available guidelines’ recommendations on RT are based on studies with a low level of evidence, where two-dimensional (2D)-RT was widely used. Methods A systematic review of the recent literature regarding the optimal radiation dose for patients with TETs undergoing RT was carried out. It included reports using modern RT techniques such as 3D-CRT, intensity-modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT), or proton therapy. A comprehensive literature search of four databases was conducted following the PRISMA guidelines. Two investigators independently screened and reviewed the retrieved references. Reports with <20 patients, 2D-RT use only, median follow-up time 3 years, three additional studies could be evaluated. A total of 193 patients were analyzed, stratified for prognostic factors (histology, stage, and completeness of resection), and synthesized according to the SWIM method. The paucity and heterogeneity of eligible studies led to controversial results. Overall, a dose escalation for post-operative RT beyond 50 Gy is not recommended for totally resected tumors, platinum-based chemo plus concurrent RT >54 Gy is recommended for unresectable TETs, while a dose below 52 Gy has been defined as \"palliative\" for recurrent TETs. Conclusions The optimal RT dose for postoperative or primary RT in the era of modern RT did not univocally emerge. Current recommendations remain valid. Doses of 54 Gy or higher can be recommended for definitive RT only. Conversely, this overview can spark new evidence to define the optimal RT dose for each TETs category.","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43862237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AB001. Surgical resection followed by entire hemithorax irradiation in patients with stage IVa thymoma: preliminary result of a prospective phase II study AB001。IVa期胸腺瘤患者手术切除后全半胸放疗:一项前瞻性II期研究的初步结果
Pub Date : 2022-12-01 DOI: 10.21037/med-22-ab001
Changlu Wang, Qin Zhang, Xiao-long Fu, Z. Gu, T. Mao, W. Fang
Background The aim of this study is to evaluate the safety and tumor-control effect of macroscopically surgical resection plus low-dose hemithorax irradiation in this group of patients. Methods This clinical trial was registered in April 2020 (ChiCTR2000035540). Patients enrolled in this study meet the following criteria: (I) pathologically confirmed thymoma, (II) with pleural dissemination (de-novo or recurrence), (III) removal of all visible lesions by surgical resection, (IV) age between 18 and 75 years. Radiotherapy was carried out 4–6 weeks after surgery via intensity modulated radiotherapy (IMRT) technique. The clinical target volume (CTV) covered the entire ipsilateral pleura and lung structure. A 4–6 mm margin was added beyond CTV to form the planning target volume (PTV). The radiation dose was 14 Gy in 14 fractions. A boost radiation (30 Gy/15 fraction) will be delivered to mediastinal tumor bed if the T stage is beyond T2. Progression-free survival (PFS) and toxicity were recorded as main end-points. Results From April 2020 to July 2021, a total of 65 patients have been enrolled in this trial. There were 29 male and 36 female patients with the age ranging between 27 and 75 years. The pathological subtypes were A (n=2), AB (n=2), B1 (n=11), B2 (n=23) and B3 (n=27), respectively. Thirty-five patients received previous surgery and developed pleural recurrence before this study, and 27 of them also underwent mediastinal tumor bed radiotherapy (≤50 Gy). The other 30 patients were diagnosed as primary thymoma with pleural dissemination. After surgery, 61 patients completed the hemithorax radiotherapy without severe side effects. The most common adverse events were fatigue, appetite loss and vomiting, and most of them were mild. Two patients suspended treatment at 6 Gy due to fatigue and resumed the therapy after 1–2 weeks of rest. One patient discontinued treatment due to grade 3 thrombocytopenia at 6 Gy, another patient discontinued treatment due to weakness at 8 Gy. After a median follow-up of 18 (10–25) months, 5 (7.7%) patients developed pleural recurrence. By the cut-off time, the disease control rate is 92.3%. Conclusions Prophylactic entire hemithorax radiotherapy after surgical resection is a safe and effective treatment modality for patients with stage IVa thymoma.
背景本研究的目的是评估该组患者行宏观手术切除加低剂量半胸照射的安全性和肿瘤控制效果。方法本临床试验于2020年4月注册(ChiCTR200035540)。参与本研究的患者符合以下标准:(I)经病理证实的胸腺瘤,(II)胸膜播散(新发或复发),(III)通过手术切除所有可见病变,(IV)年龄在18至75岁之间。放射治疗在手术后4-6周通过强度调制放射治疗(IMRT)技术进行。临床目标体积(CTV)覆盖了整个同侧胸膜和肺结构。在CTV之外增加了4-6 mm的裕度,以形成计划目标体积(PTV)。辐射剂量为14 Gy,分为14个部分。如果T分期超过T2,则将增强放射(30Gy/15级)输送至纵隔肿瘤床。无进展生存期(PFS)和毒性被记录为主要终点。结果从2020年4月到2021年7月,共有65名患者参加了该试验。共有29名男性和36名女性患者,年龄在27岁至75岁之间。病理亚型分别为A(n=2)、AB(n=2中)、B1(n=11)、B2(n=23)和B3(n=27)。35名患者在本研究之前接受过手术并出现胸膜复发,其中27人还接受了纵隔肿瘤床放疗(≤50 Gy)。其他30例患者被诊断为原发性胸腺瘤伴胸膜播散。术后61例患者完成了半胸放疗,无严重副作用。最常见的不良事件是疲劳、食欲不振和呕吐,大多数是轻微的。两名患者因疲劳暂停了6 Gy的治疗,并在休息1-2周后恢复治疗。一名患者因6 Gy时出现3级血小板减少症而停止治疗,另一名患者则因8 Gy时虚弱而停止治疗。中位随访18(10-25)个月后,5名(7.7%)患者出现胸膜复发。结论IVa期胸腺瘤术后预防性全半胸放疗是一种安全有效的治疗方法。
{"title":"AB001. Surgical resection followed by entire hemithorax irradiation in patients with stage IVa thymoma: preliminary result of a prospective phase II study","authors":"Changlu Wang, Qin Zhang, Xiao-long Fu, Z. Gu, T. Mao, W. Fang","doi":"10.21037/med-22-ab001","DOIUrl":"https://doi.org/10.21037/med-22-ab001","url":null,"abstract":"Background The aim of this study is to evaluate the safety and tumor-control effect of macroscopically surgical resection plus low-dose hemithorax irradiation in this group of patients. Methods This clinical trial was registered in April 2020 (ChiCTR2000035540). Patients enrolled in this study meet the following criteria: (I) pathologically confirmed thymoma, (II) with pleural dissemination (de-novo or recurrence), (III) removal of all visible lesions by surgical resection, (IV) age between 18 and 75 years. Radiotherapy was carried out 4–6 weeks after surgery via intensity modulated radiotherapy (IMRT) technique. The clinical target volume (CTV) covered the entire ipsilateral pleura and lung structure. A 4–6 mm margin was added beyond CTV to form the planning target volume (PTV). The radiation dose was 14 Gy in 14 fractions. A boost radiation (30 Gy/15 fraction) will be delivered to mediastinal tumor bed if the T stage is beyond T2. Progression-free survival (PFS) and toxicity were recorded as main end-points. Results From April 2020 to July 2021, a total of 65 patients have been enrolled in this trial. There were 29 male and 36 female patients with the age ranging between 27 and 75 years. The pathological subtypes were A (n=2), AB (n=2), B1 (n=11), B2 (n=23) and B3 (n=27), respectively. Thirty-five patients received previous surgery and developed pleural recurrence before this study, and 27 of them also underwent mediastinal tumor bed radiotherapy (≤50 Gy). The other 30 patients were diagnosed as primary thymoma with pleural dissemination. After surgery, 61 patients completed the hemithorax radiotherapy without severe side effects. The most common adverse events were fatigue, appetite loss and vomiting, and most of them were mild. Two patients suspended treatment at 6 Gy due to fatigue and resumed the therapy after 1–2 weeks of rest. One patient discontinued treatment due to grade 3 thrombocytopenia at 6 Gy, another patient discontinued treatment due to weakness at 8 Gy. After a median follow-up of 18 (10–25) months, 5 (7.7%) patients developed pleural recurrence. By the cut-off time, the disease control rate is 92.3%. Conclusions Prophylactic entire hemithorax radiotherapy after surgical resection is a safe and effective treatment modality for patients with stage IVa thymoma.","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43423868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AB010. Clinical significance of serum Cyfra 21-1 as a marker in thymic epithelial tumors AB010。血清Cyfra 21-1作为胸腺上皮肿瘤标志物的临床意义
Pub Date : 2022-12-01 DOI: 10.21037/med-22-ab010
Xiuxiu Hao, Xuefei Zhang, Wen-xu Fang
Background There have been no specific serum biomarkers for thymic epithelial tumors (TETs) yet. The study aimed to explore the diagnostic and prognostic value of potentially relevant serum tumor markers in TETs. Methods We retrospectively analyzed the database of our own with the aim of reviewing the clinical records of 301 patients who have a thymic epithelial tumor after radical thymectomy, in the period between November 2012 and December 2017. Logistic regression analysis was used to evaluate relationships between tumor markers and tumor characteristics. Cox regression analysis and Kaplan Meier analysis were used to evaluate free-from-recurrence (FFR) in complete resected (R0) patients. Results There were 231 (76.7%) thymoma patients, 70 (23.3%) thymic carcinomas (TCs) and neuroendocrine thymic tumors (NETTs) patients in the study. The carcinoembryonic antigen (CEA), Cyfra 21-1, squamous cell carcinoma (SCC) antigen, neuron-specific enolase (NSE), and cancer antigen 125 (CA125) levels were evaluated. Elevated Cyfra 21-1, older age, higher T stage, and N stage were associated with TCs and NETTs in multivariable logistic regression analysis. In 222 patients who received R0 resection without neoadjuvant therapy, elevated Cyfra 21-1, higher T stage, and TCs and NETTs were associated with a poorer 5-year FFR in Cox regression analysis. There were significant differences in 5-year FFR between an elevated Cyfra 21-1 level and a normal Cyfra 21-1 level (42.9% vs. 92.4%, P<0.001). As for histological subtypes, TCs and NETTs were associated with a poorer 5-year FFR than thymomas (59.8% vs. 95.0%, P<0.001). Conclusions Serum Cyfra 21-1 level could be a potential tumor marker in the diagnosis of thymic carcinomas and NETTs, and the prognosis of recurrence.
背景胸腺上皮肿瘤(TETs)尚无特异性血清生物标志物。本研究旨在探讨潜在相关血清肿瘤标志物在TETs中的诊断和预后价值。方法我们回顾性分析了我们自己的数据库,目的是回顾2012年11月至2017年12月期间301名胸腺上皮肿瘤根治术后患者的临床记录。Logistic回归分析用于评估肿瘤标志物和肿瘤特征之间的关系。Cox回归分析和Kaplan-Meier分析用于评估完全切除(R0)患者的无复发(FFR)。结果本研究共有231例(76.7%)胸腺瘤患者,70例(23.3%)胸腺癌和神经内分泌胸腺肿瘤患者。评估癌胚抗原(CEA)、Cyfra 21-1、鳞状细胞癌(SCC)抗原、神经元特异性烯醇化酶(NSE)和癌症抗原125(CA125)水平。在多变量逻辑回归分析中,Cyfra 21-1升高、年龄较大、T分期较高和N分期与TC和NETT相关。Cox回归分析显示,在222例未接受新辅助治疗的R0切除患者中,Cyfra 21-1升高、T分期升高、TC和NETT与5年FFR较差相关。Cyfra 21-1水平升高和正常Cyfra 21 1水平之间的5年期血流储备分数存在显著差异(42.9%对92.4%,P<0.001)。就组织学亚型而言,TCs和NETT与5年期FFR较差有关,而与胸腺瘤(59.8%对95.0%,P<001)有关,以及复发的预后。
{"title":"AB010. Clinical significance of serum Cyfra 21-1 as a marker in thymic epithelial tumors","authors":"Xiuxiu Hao, Xuefei Zhang, Wen-xu Fang","doi":"10.21037/med-22-ab010","DOIUrl":"https://doi.org/10.21037/med-22-ab010","url":null,"abstract":"Background There have been no specific serum biomarkers for thymic epithelial tumors (TETs) yet. The study aimed to explore the diagnostic and prognostic value of potentially relevant serum tumor markers in TETs. Methods We retrospectively analyzed the database of our own with the aim of reviewing the clinical records of 301 patients who have a thymic epithelial tumor after radical thymectomy, in the period between November 2012 and December 2017. Logistic regression analysis was used to evaluate relationships between tumor markers and tumor characteristics. Cox regression analysis and Kaplan Meier analysis were used to evaluate free-from-recurrence (FFR) in complete resected (R0) patients. Results There were 231 (76.7%) thymoma patients, 70 (23.3%) thymic carcinomas (TCs) and neuroendocrine thymic tumors (NETTs) patients in the study. The carcinoembryonic antigen (CEA), Cyfra 21-1, squamous cell carcinoma (SCC) antigen, neuron-specific enolase (NSE), and cancer antigen 125 (CA125) levels were evaluated. Elevated Cyfra 21-1, older age, higher T stage, and N stage were associated with TCs and NETTs in multivariable logistic regression analysis. In 222 patients who received R0 resection without neoadjuvant therapy, elevated Cyfra 21-1, higher T stage, and TCs and NETTs were associated with a poorer 5-year FFR in Cox regression analysis. There were significant differences in 5-year FFR between an elevated Cyfra 21-1 level and a normal Cyfra 21-1 level (42.9% vs. 92.4%, P<0.001). As for histological subtypes, TCs and NETTs were associated with a poorer 5-year FFR than thymomas (59.8% vs. 95.0%, P<0.001). Conclusions Serum Cyfra 21-1 level could be a potential tumor marker in the diagnosis of thymic carcinomas and NETTs, and the prognosis of recurrence.","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48825568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Mediastinum (Hong Kong, China)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1